143 related articles for article (PubMed ID: 16595064)
21. Phase I combining a P-glycoprotein inhibitor, MS209, in combination with docetaxel in patients with advanced malignancies.
Diéras V; Bonneterre J; Laurence V; Degardin M; Pierga JY; Bonneterre ME; Marreaud S; Lacombe D; Fumoleau P
Clin Cancer Res; 2005 Sep; 11(17):6256-60. PubMed ID: 16144929
[TBL] [Abstract][Full Text] [Related]
22. Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies.
Fracasso PM; Rodriguez LC; Herzog TJ; Fears CL; Goodner SA; Govindan R; Picus J; Rader JS; Tan BR; Arquette MA
Cancer; 2003 Aug; 98(3):610-7. PubMed ID: 12879480
[TBL] [Abstract][Full Text] [Related]
23. Phase I trial of paclitaxel, carboplatin, and topotecan with or without filgrastim (granulocyte-colony stimulating factor) in the treatment of patients with advanced, refractory cancer.
Hainsworth JD; Burris HA; Morrissey LH; Greco FA
Cancer; 1999 Mar; 85(5):1179-85. PubMed ID: 10091804
[TBL] [Abstract][Full Text] [Related]
24. A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours.
Pronk LC; Vasey P; Sparreboom A; Reigner B; Planting AS; Gordon RJ; Osterwalder B; Verweij J; Twelves C
Br J Cancer; 2000 Jul; 83(1):22-9. PubMed ID: 10883663
[TBL] [Abstract][Full Text] [Related]
25. Phase I study of alternating doublets of topotecan/carboplatin and paclitaxel/carboplatin in patients with newly diagnosed, advanced ovarian cancer.
Gordon AN; Hancock KC; Matthews CM; Messing M; Stringer CA; Doherty MG; Teneriello M
Gynecol Oncol; 2002 Apr; 85(1):129-35. PubMed ID: 11925132
[TBL] [Abstract][Full Text] [Related]
26. A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies.
Chiorean EG; Porter JM; Foster AE; Al Omari AS; Yoder CA; Fife KL; Strother RM; Murry DJ; Yu M; Jones DR; Sweeney CJ
Clin Cancer Res; 2008 Feb; 14(4):1131-7. PubMed ID: 18281547
[TBL] [Abstract][Full Text] [Related]
27. Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects.
de Jonge MJ; Loos WJ; Gelderblom H; Planting AS; van der Burg ME; Sparreboom A; Brouwer E; van Beurden V; Mantel MA; Doyle E; Hearn S; Ross G; Verweij J
J Clin Oncol; 2000 May; 18(10):2104-15. PubMed ID: 10811676
[TBL] [Abstract][Full Text] [Related]
28. Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.
Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Blum RH; Zeleniuch-Jacquotte A
Clin Cancer Res; 1997 Aug; 3(8):1245-52. PubMed ID: 9815806
[TBL] [Abstract][Full Text] [Related]
29. Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors.
Daw NC; Santana VM; Iacono LC; Furman WL; Hawkins DR; Houghton PJ; Panetta JC; Gajjar AJ; Stewart CF
J Clin Oncol; 2004 Mar; 22(5):829-37. PubMed ID: 14990638
[TBL] [Abstract][Full Text] [Related]
30. Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks.
Kerbusch T; Groenewegen G; Mathôt RA; Herben VM; ten Bokkel Huinink WW; Swart M; Ambaum B; Rosing H; Jansen S; Voest EE; Beijnen JH; Schellens JH
Br J Cancer; 2004 Jun; 90(12):2268-77. PubMed ID: 15150579
[TBL] [Abstract][Full Text] [Related]
31. A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies.
Tolcher AW; O'Shaughnessy JA; Weiss RB; Zujewski J; Myhand RC; Schneider E; Hakim F; Gress R; Goldspiel B; Noone MH; Brewster LR; Gossard MR; Cowan KH
Clin Cancer Res; 1997 May; 3(5):755-60. PubMed ID: 9815746
[TBL] [Abstract][Full Text] [Related]
32. Relationship of systemic exposure to unbound docetaxel and neutropenia.
Baker SD; Li J; ten Tije AJ; Figg WD; Graveland W; Verweij J; Sparreboom A
Clin Pharmacol Ther; 2005 Jan; 77(1):43-53. PubMed ID: 15637530
[TBL] [Abstract][Full Text] [Related]
33. A phase I dose escalation study of weekly docetaxel and carboplatin in elderly patients with nonsmall cell lung cancer.
Kaira K; Tsuchiya S; Sunaga N; Yanagitani N; Watanabe S; Imai H; Hisada T; Ishizuka T; Saito R; Mori M
Am J Clin Oncol; 2007 Feb; 30(1):51-6. PubMed ID: 17278895
[TBL] [Abstract][Full Text] [Related]
34. Study of dose escalation and sequence switching of administration of the combination of docetaxel and doxorubicin in advanced breast cancer.
Itoh K; Sasaki Y; Fujii H; Minami H; Ohtsu T; Wakita H; Igarashi T; Watanabe Y; Onozawa Y; Kashimura M; Ohashi Y
Clin Cancer Res; 2000 Oct; 6(10):4082-90. PubMed ID: 11051260
[TBL] [Abstract][Full Text] [Related]
35. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
36. A phase I clinical and pharmacokinetic study of tipifarnib in combination with docetaxel in patients with advanced solid malignancies.
Awada A; Zhang S; Gil T; de Valeriola D; Lalami Y; De Porre P; Piccart-Gebhart MJ
Curr Med Res Opin; 2007 May; 23(5):991-1003. PubMed ID: 17519066
[TBL] [Abstract][Full Text] [Related]
37. Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours.
Awada A; Hendlisz A; Christensen O; Lathia CD; Bartholomeus S; Lebrun F; de Valeriola D; Brendel E; Radtke M; Delaunoit T; Piccart-Gebhart M; Gil T
Eur J Cancer; 2012 Mar; 48(4):465-74. PubMed ID: 22285181
[TBL] [Abstract][Full Text] [Related]
38. A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors.
Felici A; Loos WJ; Verweij J; Cirillo I; de Bruijn P; Nooter K; Mathijssen RH; de Jonge MJ
Cancer Chemother Pharmacol; 2006 Nov; 58(5):673-80. PubMed ID: 16544143
[TBL] [Abstract][Full Text] [Related]
39. Myelotoxicity of oral topotecan in relation to treatment duration and dosage: a phase I study.
Stathopoulos GP; Ardavanis A; Papakotoulas P; Pectasides D; Papadopoulos G; Antoniou D; Athanasiadis A; Trafalis D; Anagnostopoulos A; Koutantos J; Vaslamatzis M
Anticancer Drugs; 2010 Feb; 21(2):202-5. PubMed ID: 20010424
[TBL] [Abstract][Full Text] [Related]
40. Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer.
Tan AR; Yang X; Berman A; Zhai S; Sparreboom A; Parr AL; Chow C; Brahim JS; Steinberg SM; Figg WD; Swain SM
Clin Cancer Res; 2004 Aug; 10(15):5038-47. PubMed ID: 15297405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]